home / stock / urgn / urgn quote
Last: | $14.15 |
---|---|
Change Percent: | -1.09% |
Open: | $13.97 |
Close: | $14.15 |
High: | $14.32 |
Low: | $13.69 |
Volume: | 135,569 |
Last Trade Date Time: | 04/26/2024 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$14.15 | $13.97 | $14.15 | $14.32 | $13.69 | 135,569 | 04-26-2024 |
$13.82 | $14.05 | $13.82 | $14.5 | $13.77 | 185,411 | 04-25-2024 |
$14.21 | $14.66 | $14.21 | $14.758 | $14.19 | 97,025 | 04-24-2024 |
$14.53 | $14.4 | $14.53 | $14.85 | $14.11 | 216,754 | 04-23-2024 |
$14.37 | $13.8 | $14.37 | $14.52 | $13.58 | 278,571 | 04-22-2024 |
$13.73 | $14.06 | $13.73 | $14.28 | $13.17 | 389,484 | 04-19-2024 |
$14.26 | $14.36 | $14.26 | $14.54 | $13.96 | 315,348 | 04-18-2024 |
$14.24 | $14.61 | $14.24 | $14.66 | $14.02 | 187,493 | 04-17-2024 |
$14.49 | $14.86 | $14.49 | $15.05 | $14.15 | 409,956 | 04-16-2024 |
$15.1 | $15.32 | $15.1 | $15.5 | $14.21 | 661,676 | 04-15-2024 |
$15.1 | $13.09 | $15.1 | $15.21 | $13 | 1,228,983 | 04-12-2024 |
$13.25 | $13.14 | $13.25 | $13.25 | $12.37 | 258,705 | 04-11-2024 |
$12.95 | $13.2 | $12.95 | $13.2 | $12.58 | 378,477 | 04-10-2024 |
$13.37 | $13.32 | $13.37 | $13.91 | $13.21 | 204,206 | 04-09-2024 |
$13.21 | $13.64 | $13.21 | $13.64 | $13.18 | 125,207 | 04-08-2024 |
$13.6 | $13.54 | $13.6 | $13.98 | $13.214 | 128,770 | 04-05-2024 |
$13.64 | $13.77 | $13.64 | $14.3 | $13.5 | 236,482 | 04-04-2024 |
$13.66 | $14 | $13.66 | $14.26 | $13.47 | 176,361 | 04-03-2024 |
$14.09 | $14.28 | $14.09 | $14.515 | $13 | 194,218 | 04-02-2024 |
$14.2 | $14.75 | $14.2 | $14.75 | $14.16 | 195,468 | 04-01-2024 |
News, Short Squeeze, Breakout and More Instantly...
UroGen Pharma Ltd. Company Name:
URGN Stock Symbol:
NASDAQ Market:
Subgroup analysis of the UGN-102 ATLAS Trial in patients with new versus recurrent low-grade intermediate-risk non-muscle invasive bladder cancer (LG-IR-NMIBC) Three independent long-term real-world analyses of JELMYTO® (mitomycin) for pyelocalyceal solution exploring its use in broad pa...
UroGen plans to initiate a Phase 3 study to explore the safety and efficacy of UGN-103 in 2024 Anticipated advantages include a new 80 mg mitomycin dosage strength that may considerably shorten the manufacturing process, simplify the reconstitution procedure, and potentially extend intellectu...
UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing novel solutions that treat urothelial and specialty cancers, today announced that it has filed a lawsuit in the U.S. District Court for the District of Delaware against Teva Pharmaceuticals, Inc., Tev...